CHRS fundamentals
An in-depth look to Coherus BioSciences, Inc. operating, investing, and financing activities
CHRS free cash flow for Q3 24 is -62.02 M USD. For 2023, CHRS free cash flow was -175.17 M USD and operating cash flow was -174.88 M USD.
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
TTM